(firstQuint)Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes.

 TAK-875 is being developed at Takeda Development Center, Inc.

 as an adjunct to diet and exercise to improve glycemic control in patients with T2DM.

 This study will investigate TAK-875 in participants with type 2 diabetes mellitus who have been treated with only diet and exercise for at least 12 weeks prior to Screening, who have taken 7 days of any antidiabetic agent within the 12 weeks prior to Screening, and whose glycemic control is inadequate.

.

 Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes@highlight

The purpose of this study is to determine the efficacy and safety of TAK-875 (fasiglifam), once daily (QD), in participants with type 2 diabetes mellitus (T2DM).

